Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.

Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):186-91. doi: 10.3816/CLML.2010.n.029.

PMID:
20511163
2.

A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.

Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N.

Haematologica. 2008 Mar;93(3):405-12. doi: 10.3324/haematol.11287. Epub 2008 Feb 11.

3.

BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.

Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C.

Ann Hematol. 2008 Jan;87(1):43-8. Epub 2007 Aug 21.

PMID:
17710401
4.

High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.

Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.

Bone Marrow Transplant. 1996 Feb;17(2):149-55.

PMID:
8640159
5.

Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.

Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G, Console G, Iacopino P.

Eur J Haematol. 2006 Nov;77(5):410-5. Epub 2006 Aug 23.

PMID:
16930141
6.

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).

Sebban C, Lefranc A, Perrier L, Moreau P, Espinouse D, Schmidt A, Kammoun L, Ghesquieres H, Ferlay C, Bay JO, Lissandre S, Pérol D, Michallet M, Quittet P.

Eur J Cancer. 2012 Mar;48(5):713-20. doi: 10.1016/j.ejca.2011.12.016. Epub 2012 Jan 14.

PMID:
22248711
7.

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.

Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A.

Lancet. 1996 Feb 10;347(8998):353-7. Erratum in: Lancet 1996 Mar 30;347(9005):914.

PMID:
8598700
8.

Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.

Kroschinsky F, Hölig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, Oelschlaegel U, Schaich M, Hänel M, Bornhäuser M, Ehninger G.

Transfusion. 2006 Aug;46(8):1417-23.

PMID:
16934080
9.

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC.

J Clin Oncol. 2003 Feb 1;21(3):514-9.

PMID:
12560443
11.

Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.

Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C.

Appl Health Econ Health Policy. 2013 Apr;11(2):129-38. doi: 10.1007/s40258-013-0011-7.

PMID:
23435861
12.

Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.

Samaras P, Buset EM, Siciliano RD, Haile SR, Petrausch U, Mischo A, Honegger H, Pestalozzi BC, Schanz U, Stussi G, Stahel RA, Knuth A, Renner C, Stenner-Liewen F.

Oncology. 2010;79(1-2):93-7. doi: 10.1159/000320604. Epub 2010 Nov 15.

PMID:
21079406
13.

Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.

Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG.

Bone Marrow Transplant. 2005 Jun;35(12):1165-9.

PMID:
15880129
14.
15.
16.

Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.

Pettengell R, Morgenstern GR, Woll PJ, Chang J, Rowlands M, Young R, Radford JA, Scarffe JH, Testa NG, Crowther D.

Blood. 1993 Dec 15;82(12):3770-7.

17.
18.
19.

Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT.

Kawano Y, Takaue Y, Mimaya J, Horikoshi Y, Watanabe T, Abe T, Shimizu Y, Matsushita T, Kikuta A, Watanabe A, Iwai A, Ito E, Endo M, Kodani N, Ohta S, Gushi K, Azuma H, Etoh T, Okamoto Y, Amano K, Hattori H, Eguchi H, Kuroda Y.

Blood. 1998 Dec 1;92(11):4040-6.

20.

Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Kahl C, Sayer HG, Hinke A, Freund M, Casper J.

J Cancer Res Clin Oncol. 2012 Mar;138(3):513-7. doi: 10.1007/s00432-011-1116-8. Epub 2011 Dec 25.

PMID:
22198675

Supplemental Content

Support Center